Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer

Trial Details

NCT ID

NCT06566755

Phase

PHASE3

Sponsor

Caigang Liu

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

• Cadonilimab (AK104) combined with chemotherapy and bevacizumab

Locations (sample)

• Shenyang, Liaoning, China|41.79222,123.43278

Key Eligibility Criteria

• Able to understand and voluntarily sign a written informed consent form, which must be signed before the designated research procedures required fo…
• Age at the time of signing the Informed Consent Form (ICF) is ≥ 18 years old and ≤ 75 years old, both male and female.
• The Eastern Cancer Collaborative Organization (ECOG) has a physical fitness score of 0 or 1.
• The expected survival period is ≥ 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.